Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Shaddy, R., Burch, M., Kantor, P. F., Solar-Yohay, S., Garito, T., Zhang, S., Kocun, M., Mao, C., Cilliers, A., Wang, X., Canter, C., Rossano, J., Wallis, G., Menteer, J., Daou, L., Kusa, J., Tokel, K., Dilber, D., Xu, Z., … Zuhlke, L. (2024). Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation, 150(22), 1756–1766. https://doi.org/10.1161/circulationaha.123.066605

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology, 59(12), 3641–3649. Portico. https://doi.org/10.1002/ppul.27273

Rose, N. R., Chalamalla, A. R., Garcia, B. A., Krick, S., Bergeron, J., Sadeghi, H., Schellhase, D. E., Ryan, K. J., Dowell, A. E., Acosta, E. P., & Guimbellot, J. S. (2024). Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulmonary Pharmacology & Therapeutics, 86, 102301. https://doi.org/10.1016/j.pupt.2024.102301

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702